Advertisement

Use of fish oil and mortality of patients with cardiometabolic multimorbidity: A prospective study of UK biobank

  • Tianqi Ma
    Affiliations
    Department of Geriatric Medicine, Center of Coronary Circulation, Xiangya Hospital, Central South University, Changsha, 410008, China

    National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, China
    Search for articles by this author
  • Lingfang He
    Affiliations
    Department of Geriatric Medicine, Center of Coronary Circulation, Xiangya Hospital, Central South University, Changsha, 410008, China

    National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, China
    Search for articles by this author
  • Yi Luo
    Affiliations
    Department of Geriatric Medicine, Center of Coronary Circulation, Xiangya Hospital, Central South University, Changsha, 410008, China

    National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, China
    Search for articles by this author
  • Guogang Zhang
    Affiliations
    Department of Cardiovascular Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China

    Department of Cardiovascular Medicine, The Third Xiangya Hospital, Central South University, Changsha, 410013, China
    Search for articles by this author
  • Xunjie Cheng
    Correspondence
    Corresponding author. Department of Geriatric Medicine, Xiangya Hospital, Central South University, Xiangya Road 87#, Changsha, 410008, China. Fax: +86 0731 84327695.
    Affiliations
    Department of Geriatric Medicine, Center of Coronary Circulation, Xiangya Hospital, Central South University, Changsha, 410008, China

    National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, China
    Search for articles by this author
  • Yongping Bai
    Correspondence
    Corresponding author. Department of Geriatric Medicine, Xiangya Hospital, Central South University, Xiangya Road 87#, Changsha, 410008, China. Fax: +86 0731 84327695.
    Affiliations
    Department of Geriatric Medicine, Center of Coronary Circulation, Xiangya Hospital, Central South University, Changsha, 410008, China

    National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, China
    Search for articles by this author
Published:September 28, 2022DOI:https://doi.org/10.1016/j.numecd.2022.09.016

      Highlights

      • Fish oil use was associated with a lower risk of death in patients with cardiometabolic multimorbidity (CMM).
      • Using fish oil was associated with an extended life expectancy of people with CMM.
      • Protection of fish oil consistent across disease numbers, varied according to patterns.

      Abstract

      Background and aims

      Cardiometabolic multimorbidity (CMM) has risen as a global issue of public health, with an in-creasing prevalence and more severe clinical prognosis. This study aimed to estimate the association between use of fish oil and mortality among patients with CMM.

      Methods and Results

      In this prospective study based on UK Biobank, participants with ≥2 of cardiometabolic diseases (CMDs, including coronary heart disease [CHD], diabetes, hypertension, and stroke in this study) at recruitment were included. Use of fish oil was derived from touchscreen questionnaires at baseline. All-cause and cardiovascular mortality were accessed via electronic health-related records. Kaplan–Meier curves and flexible parametric Royston-Parmar proportion-hazard models were fitted to assess the as-sociations of fish-oil use with all-cause, cardiovascular mortality, and related life expectancy alterations. Among 30 068 participants from UK Biobank (67.9% men; mean age 61.75 years), 5357 deaths were reported during 12.03 years of follow-up. For patients with CMM, use of fish oil was associated with a 17% lower risk of all-cause mortality (95% confidence interval [95% CI] 0.78–0.88, P < 0.001), and 19% lower risk of cardiovascular mortality (95% CI 0.72–0.90, P < 0.001) in multivariable-adjusted models. At 45 years old, using fish oil was associated with 1.66 years of life expectancy gained.

      Conclusion

      Among patients with CMM, use of fish oil was associated with a significantly reduced risk of all-cause, cardiovascular mortality, and prolonged life expectancy.

      Keywords

      Abbreviations:

      BMI (body mass index), CHD (coronary heart disease), CMDs (cardiometabolic diseases), CMM (cardiometabolic multimorbidity), ICD (International Classification of Diseases), n-3 PUFAs (omega-3 polyunsaturated fatty acids), RMST (restricted mean survival time)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Nutrition, Metabolism and Cardiovascular Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Barnett K.
        • Mercer S.W.
        • Norbury M.
        • Watt G.
        • Wyke S.
        • Guthrie B.
        Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study.
        Lancet. 2012; 380: 37-43
        • Zhang D.
        • Tang X.
        • Shen P.
        • Si Y.
        • Liu X.
        • Xu Z.
        • et al.
        Multimorbidity of cardiometabolic diseases: prevalence and risk for mortality from one million Chinese adults in a longitudinal cohort study.
        BMJ Open. 2019; 9e024476
        • Cheng X.
        • Ma T.
        • Ouyang F.
        • Zhang G.
        • Bai Y.
        Trends in the prevalence of cardiometabolic multimorbidity in the United States, 1999-2018.
        Int J Environ Res Publ Health. 2022; 19
        • Emerging Risk Factors C.
        • Di Angelantonio E.
        • Kaptoge S.
        • Wormser D.
        • Willeit P.
        • Butterworth A.S.
        • et al.
        Association of cardiometabolic multimorbidity with mortality.
        JAMA. 2015; 314: 52-60
        • Wang Z.
        • Peng W.
        • Li M.
        • Li X.
        • Yang T.
        • Li C.
        • et al.
        Association between multimorbidity patterns and disability among older people covered by long-term care insurance in Shanghai, China.
        BMC Publ Health. 2021; 21: 418
        • Maddaloni E.
        • D'Onofrio L.
        • Alessandri F.
        • Mignogna C.
        • Leto G.
        • Pascarella G.
        • et al.
        Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II).
        Cardiovasc Diabetol. 2020; 19: 164
        • McQueenie R.
        • Foster H.M.E.
        • Jani B.D.
        • Katikireddi S.V.
        • Sattar N.
        • Pell J.P.
        • et al.
        Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort.
        PLoS One. 2020; 15e0238091
        • Singh-Manoux A.
        • Fayosse A.
        • Sabia S.
        • Tabak A.
        • Shipley M.
        • Dugravot A.
        • et al.
        Clinical, socioeconomic, and behavioural factors at age 50 years and risk of cardiometabolic multimorbidity and mortality: a cohort study.
        PLoS Med. 2018; 15e1002571
        • Freisling H.
        • Viallon V.
        • Lennon H.
        • Bagnardi V.
        • Ricci C.
        • Butterworth A.S.
        • et al.
        Lifestyle factors and risk of multimorbidity of cancer and cardiometabolic diseases: a multinational cohort study.
        BMC Med. 2020; 18: 5
        • Agbabiaka T.B.
        • Spencer N.H.
        • Khanom S.
        • Goodman C.
        Prevalence of drug-herb and drug-supplement interactions in older adults: a cross-sectional survey.
        Br J Gen Pract. 2018; 68: e711-e717
        • Kantor E.D.
        • Rehm C.D.
        • Du M.
        • White E.
        • Giovannucci E.L.
        Trends in dietary supplement use among US adults from 1999-2012.
        JAMA. 2016; 316: 1464-1474
        • Hu Y.
        • Hu F.B.
        • Manson J.E.
        Marine omega-3 supplementation and cardiovascular disease: an updated meta-analysis of 13 randomized controlled trials involving 127 477 participants.
        J Am Heart Assoc. 2019; 8e013543
        • Siscovick D.S.
        • Barringer T.A.
        • Fretts A.M.
        • Wu J.H.
        • Lichtenstein A.H.
        • Costello R.B.
        • et al.
        Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American heart association.
        Circulation. 2017; 135: e867-e884
        • Li Z.H.
        • Zhong W.F.
        • Liu S.
        • Kraus V.B.
        • Zhang Y.J.
        • Gao X.
        • et al.
        Associations of habitual fish oil supplementation with cardiovascular outcomes and all cause mortality: evidence from a large population based cohort study.
        BMJ. 2020; 368: m456
        • Ma T.
        • He L.
        • Luo Y.
        • Li J.
        • Zhang G.
        • Cheng X.
        • et al.
        Associations of baseline use of fish oil with progression of cardiometabolic multimorbidity and mortality among patients with hypertension: a prospective study of UK Biobank.
        Eur J Nutr. 2022; 61: 3461-3470
        • Sudlow C.
        • Gallacher J.
        • Allen N.
        • Beral V.
        • Burton P.
        • Danesh J.
        • et al.
        UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age.
        PLoS Med. 2015; 12e1001779
        • Innes J.K.
        • Calder P.C.
        Marine omega-3 (N-3) fatty acids for cardiovascular health: an update for 2020.
        Int J Mol Sci. 2020; : 21
        • Dehbi H.M.
        • Royston P.
        • Hackshaw A.
        Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards.
        BMJ. 2017; 357: j2250
        • Cheng X.
        • Ouyang F.
        • Ma T.
        • Luo Y.
        • Yin J.
        • Li J.
        • et al.
        Association of healthy lifestyle and life expectancy in patients with cardiometabolic multimorbidity: a prospective cohort study of UK biobank.
        Front Cardiovasc Med. 2022; 9830319
        • Harris W.S.
        • Tintle N.L.
        • Imamura F.
        • Qian F.
        • Korat A.V.A.
        • Marklund M.
        • et al.
        Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies.
        Nat Commun. 2021; 12: 2329
        • Zhang Y.
        • Zhuang P.
        • He W.
        • Chen J.N.
        • Wang W.Q.
        • Freedman N.D.
        • et al.
        Association of fish and long-chain omega-3 fatty acids intakes with total and cause-specific mortality: prospective analysis of 421 309 individuals.
        J Intern Med. 2018; 284: 399-417
      1. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.
        Lancet. 1999; 354: 447-455
        • Hu F.B.
        • Cho E.
        • Rexrode K.M.
        • Albert C.M.
        • Manson J.E.
        Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women.
        Circulation. 2003; 107: 1852-1857
        • Tavazzi L.
        • Maggioni A.P.
        • Marchioli R.
        • Barlera S.
        • Franzosi M.G.
        • Latini R.
        • et al.
        Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.
        Lancet. 2008; 372: 1223-1230
        • Glynn L.G.
        Multimorbidity: another key issue for cardiovascular medicine.
        Lancet. 2009; 374: 1421-1422
        • Yang B.
        • Shi M.Q.
        • Li Z.H.
        • Shi L.
        • Wang A.M.
        • Guo X.J.
        • et al.
        Effects of n-3 fatty acid supplements on cardiometabolic profiles in hypertensive patients with abdominal obesity in Inner Mongolia: a randomized controlled trial.
        Food Funct. 2019; 10: 1661-1670
        • Jacobo-Cejudo M.G.
        • Valdes-Ramos R.
        • Guadarrama-Lopez A.L.
        • Pardo-Morales R.V.
        • Martinez-Carrillo B.E.
        • Harbige L.S.
        Effect of n-3 polyunsaturated fatty acid supplementation on metabolic and inflammatory biomarkers in type 2 diabetes mellitus patients.
        Nutrients. 2017; 9
        • Guo X.F.
        • Li K.L.
        • Li J.M.
        • Li D.
        Effects of EPA and DHA on blood pressure and inflammatory factors: a meta-analysis of randomized controlled trials.
        Crit Rev Food Sci Nutr. 2019; 59: 3380-3393
        • Yang B.
        • Shi L.
        • Wang A.M.
        • Shi M.Q.
        • Li Z.H.
        • Zhao F.
        • et al.
        Lowering effects of n-3 fatty acid supplements on blood pressure by reducing plasma angiotensin II in inner Mongolia hypertensive patients: a double-blind randomized controlled trial.
        J Agric Food Chem. 2019; 67: 184-192
        • Budoff M.J.
        • Bhatt D.L.
        • Kinninger A.
        • Lakshmanan S.
        • Muhlestein J.B.
        • Le V.T.
        • et al.
        Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial.
        Eur Heart J. 2020; 41: 3925-3932
        • Royston P.
        • Parmar M.K.
        The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt.
        Stat Med. 2011; 30: 2409-2421
        • Zheng D.D.
        • Loewenstein D.A.
        • Christ S.L.
        • Feaster D.J.
        • Lam B.L.
        • McCollister K.E.
        • et al.
        Multimorbidity patterns and their relationship to mortality in the US older adult population.
        PLoS One. 2021; 16e0245053
        • Jani B.D.
        • Hanlon P.
        • Nicholl B.I.
        • McQueenie R.
        • Gallacher K.I.
        • Lee D.
        • et al.
        Relationship between multimorbidity, demographic factors and mortality: findings from the UK Biobank cohort.
        BMC Med. 2019; 17: 74
        • Bhatt D.L.
        • Steg P.G.
        • Miller M.
        • Brinton E.A.
        • Jacobson T.A.
        • Ketchum S.B.
        • et al.
        Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.
        N Engl J Med. 2019; 380: 11-22
        • Group A.S.C.
        • Bowman L.
        • Mafham M.
        • Wallendszus K.
        • Stevens W.
        • Buck G.
        • et al.
        Effects of n-3 fatty acid supplements in diabetes mellitus.
        N Engl J Med. 2018; 379: 1540-1550
        • Leon H.
        • Shibata M.C.
        • Sivakumaran S.
        • Dorgan M.
        • Chatterley T.
        • Tsuyuki R.T.
        Effect of fish oil on arrhythmias and mortality: systematic review.
        BMJ. 2008; 337: a2931
        • Rizos E.C.
        • Markozannes G.
        • Tsapas A.
        • Mantzoros C.S.
        • Ntzani E.E.
        Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis.
        Heart. 2021; 107: 150-158
        • Kromhout D.
        • Giltay E.J.
        • Geleijnse J.M.
        Alpha Omega Trial G. n-3 fatty acids and cardiovascular events after myocardial infarction.
        N Engl J Med. 2010; 363: 2015-2026
        • Weiss C.O.
        • Boyd C.M.
        • Yu Q.
        • Wolff J.L.
        • Leff B.
        Patterns of prevalent major chronic disease among older adults in the United States.
        JAMA. 2007; 298: 1160-1162
        • Feng L.
        • Jehan I.
        • de Silva H.A.
        • Naheed A.
        • Farazdaq H.
        • Hirani S.
        • et al.
        Prevalence and correlates of cardiometabolic multimorbidity among hypertensive individuals: a cross-sectional study in rural South Asia-Bangladesh, Pakistan and Sri Lanka.
        BMJ Open. 2019; 9e030584
        • Sakakibara B.M.
        • Obembe A.O.
        • Eng J.J.
        The prevalence of cardiometabolic multimorbidity and its association with physical activity, diet, and stress in Canada: evidence from a population-based cross-sectional study.
        BMC Publ Health. 2019; 19: 1361
        • Fry A.
        • Littlejohns T.J.
        • Sudlow C.
        • Doherty N.
        • Adamska L.
        • Sprosen T.
        • et al.
        Comparison of sociodemographic and health-related characteristics of UK biobank participants with those of the general population.
        Am J Epidemiol. 2017; 186: 1026-1034
        • Liu X.
        • Zhuang P.
        • Li Y.
        • Wu F.
        • Wan X.
        • Zhang Y.
        • et al.
        Association of fish oil supplementation with risk of incident dementia: a prospective study of 215,083 older adults.
        Clin Nutr. 2022; 41: 589-598
        • Colletti A.
        • Cravotto G.
        • Citi V.
        • Martelli A.
        • Testai L.
        • Cicero A.F.G.
        Advances in technologies for highly active omega-3 fatty acids from krill oil: clinical applications.
        Mar Drugs. 2021; 19
        • Weinberg R.L.
        • Brook R.D.
        • Rubenfire M.
        • Eagle K.A.
        Cardiovascular impact of nutritional supplementation with omega-3 fatty acids: JACC focus seminar.
        J Am Coll Cardiol. 2021; 77: 593-608